Safety and efficacy of endoscopic mucosal resection for the treatment of early gastric cancer: A systematic study and meta-analysis

Abstract

Author(s): Manoj Rameshachandra Vyas*, Vijay Upadhye and Renuka Jyothi R

Objective: Both gastrectomy and Endoscopic Resection (ER) are recognized as curative procedures for early-stage stomach cancer. Through this systematic review, we aimed to assess patient security, both early gastric cancer survivorship overall and disease-free cancer between ER and gastrectomy therapies.

Materials and methods: The databases PubMed, Embase and Cochrane Library were used to perform a literature search. This meta-analysis includes studies that contrasted early gastric cancer treated with ER and gastrectomy. Before March 2019, we looked for clinical trials. We conducted a systematic analysis using Stata 12.0 software.

Results: In this comprehensive review, nine papers were analysed. ER, therapy was linked to fewer surgical complications (OR=0.47, 95% CI 0.34- 0.65) and a shorter hospital stay (WMD=8.53, 95% CI 11.56 to 5.49). ER is carried out safely, reducing hospitalization and after-surgery issues instead of a gastroplasty. Recurrence rates were more significant with ER therapy than gastrectomy (HR=3.56, 95% CI 1.86-6.84), primarily for only ER therapy, resulting in the development of metachronous gastric cancers. However, ER may once more be used to effectively treat most metachronous stomach cancers and adverse effects on early-stage gastric cancer patients' overall survival. ER and gastrectomy, overall survival rate remained constant (HR=0.84, 95% CI 0.63-1.13).

Conclusion: Early gastric cancer curative treatment is acceptable with an ER or a gastrectomy. ER is superior to early gastric cancer treatment with gastrectomy patients that meet the requirements of ER therapy. However, overall survival rates are comparable, there are fewer postoperative problems, and the period of stay is shorter.

Share this article